选择性雌激素受体调节剂研究现状

丁浩; 杨帆; 蔡艺; 柴晓云; 吴秋业

doi:10.3969/j.issn.1006-0111.2016.01.001

选择性雌激素受体调节剂研究现状

doi: 10.3969/j.issn.1006-0111.2016.01.001

1.
第二军医大学药学院有机化学教研室, 上海 200433
2.
第二军医大学药学院有机化学教研室, 上海 200433;烟台大学药学院, 山东烟台 264005

Research progress on the selective estrogen receptor modulators

1.
Department of Organic Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China
2.
Department of Organic Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China;School of Pharmacy, Yantai University, Yantai 264005, China

摘要: 乳腺癌已经成为危害女性健康的主要恶性肿瘤,选择性雌激素受体调节剂作为治疗乳腺癌的有效药物越来越受到人们的广泛关注。笔者对选择性雌激素受体调节剂的研究现状进行综述。
- 雌激素 /
- 雌激素受体 /
- 选择性雌激素受体调节剂
Abstract: Breast cancer has become the main malignant tumors which pose a serious threat to women's health.Selective estrogen receptor modulators, which served as the effective drug treatment,have been attracting more attention. Present research progress on the selective estrogen receptor modulators was summarized in this paper.
- estrogen /
- estrogen receptor /
- selective estrogen receptor modulators

[1]	Advani P, Moreno-Aspitia A. Current strategies for the prevention of breast cancer[J], Breast Cancer (Dove Med Press), 2014, 6: 59-71.
[2]	郑莹, 吴春晓, 吴凡, 等. 中国女性乳腺癌死亡现况和发展趋势[J]. 中华预防医学杂志, 2011, 45(2): 150-154.
[3]	Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China[J]. Lancet Oncol, 2014, 15(7): 279-289.
[4]	Germain D. Estrogen carcinogenesis in breast cancer[J]. Endocrinol Metab Clin North Am, 2011, 40(3): 473-484.
[5]	Nelson ER, Wardell SE, McDonnell DP. The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: Implications for the treatment and prevention of osteoporosis[J]. Bone, 2013, 53(1): 42-50.
[6]	Ortona E, Pierdominici M, Berstein L. Autoantibodies to estrogen receptors and their involvement in autoimmune diseases and cancer[J]. J Steroid Biochem Mol Biol, 2014, 144: 260-267.
[7]	Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications[J]. J Clin Oncol, 2005, 23: 1616-1622.
[8]	Mirkin S, Pickar JH. Selective estrogen receptor modulators (SERMs): A review of clinical data[J]. Maturitas, 2015, 53: 52-57.
[9]	Nagaraj G, Ma C. Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer[J]. Breast Cancer Res Treat, 2015,150(2):231-242.
[10]	Shanle EK, Xu W. Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action[J]. Chem Res Toxicol, 2011, 24: 6-19.
[11]	Komm BS, Mirkin S. An overview of current and emerging SERMs[J]. J Steroid Biochem Mol Biol, 2014, 143:207-222.
[12]	Williams C, Lin CY. Oestrogen receptors in breast cancer: basic mechanisms and clinical implications[J]. Ecancermedicalscience, 2013, 7:370.
[13]	Hadji P. The evolution of selective estrogen receptor modulators in osteoporosis therapy[J]. Climacteric, 2012, 15 (6): 513-523.
[14]	Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice[J]. Curr Clin Pharmacol, 2013, 8(2): 135-155.
[15]	Jordan VC, McDaniel R, Agboke F, et al. The evolution of nonsteroidalantiestrogens to become selective estrogen receptor modulators[J]. Steroids, 2014, 90: 3-12.
[16]	Kaur G, Mahajan MP, Pandey MK. Design, synthesis and evaluation of Ospemifene analogs as anti-breast cancer agents[J]. Eur J Med Chem, 2014, 86: 211-218.
[17]	Silverman S, Christiansen C. Individualizing osteoporosis therapy[J]. Osteoporos Int, 2012, 23 (3): 797-809.
[18]	Gennari L, Merlotti D, Stolakis K, et al. Lasofoxifene, from the preclinicaldrug discovery to the treatment of postmenopausal osteoporosis[J]. Expert Opin Drug Discov, 2011, 6 (2): 205-217.
[19]	Michalsen BT, Gherezghiher TB, Choi J, et al. The selective estrogen receptor modulator (SERM) Lasofoxifeneformsreactive quinonessimilar to estradiol[J]. Chem Res Toxicol, 2012, 25(7) : 1472-1483.
[20]	Vessières A, Top S, Beck W, et al. Metal complex SERMs (selective estrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferativeeffects[J]. Dalton Trans, 2006, 4: 529-541.
[21]	Li M J, Greenblatt HM, Dym O, et al. Structure of estradiol metal chelate and estrogen receptor complex: The basis for designing a new class of selective estrogen receptor modulators[J]. J Med Chem, 2011, 54(10): 3575-3580.
[22]	Top S, Vessi res A, Leclercq G, et al. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines[J]. Chemistry, 2003, 9(21): 5223-5236.
[23]	Plazuk D, Vessi res A, Hillard EA, et al. A[3]ferrocenophane polyphenol showing a remarkable antiproliferative activity on breast and prostate cancer cell lines[J]. J Med Chem, 2009, 52(15): 4964-4967.
[24]	Jain N, Kanojia RM, Xu J, et al. Novelchromene-derived selective estrogen receptor modulators usefulfor alleviating hot flushes and vaginal dryness[J]. J Med Chem, 2006, 49(11): 3056-3059.
[25]	Jain N, Xu J, Kanojia RM, et al. Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms[J]. J Med Chem, 2009, 52: 7544-7569.
[26]	Paterni I, Granchi C, Katzenellenbogen JA, et al. Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selectiveligands and clinicalpotential[J]. Steroids, 2014, 90: 13-29.
[27]	Kim S, Wu JY, Birzin ET, et al. Estrogen Receptor Ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptorαmodulators[J]. J Med Chem, 2004, 47(9): 2171-2175.
[28]	Liao ZQ, Dong C, Carlson KE, et al. Triaryl-substitutedschiff bases are high-affinity subtype-selective ligands for the estrogenreceptor[J]. J Med Chem, 2014, 57: 3532-3545.
[29]	Carroll VM, Jeyakumar M, Carlson KE, et al. Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands[J]. J Med Chem, 2012, 55: 528-537.
[30]	Ohta K, Ogawa T, Kaise A, et al. Aliphatic substitution of ocarboranyl phenols enhances estrogen receptor beta selectivity[J]. Chem Pharm Bull, 2014, 62: 386-391.

[1]	迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛. 负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架治疗创伤性脑损伤的研究 . 药学实践与服务, 2025, 43(2): 67-74. doi: 10.12206/j.issn.2097-2024.202406034
[2]	曹金发, 钟玲, 何苗, 田泾. 炎症性肠病合并心房颤动患者的用药分析与监护 . 药学实践与服务, 2025, 43(): 1-4. doi: 10.12206/j.issn.2097-2024.202403004
[3]	张淑秀, 袁伯川, 杜丽娜, 金义光. 多糖用于放射性核素清除的研究进展 . 药学实践与服务, 2025, 43(): 1-6. doi: 10.12206/j.issn.2097-2024.202405060
[4]	徐璐璐, 刘爱军. 丹参白术方“异病同治”冠心病、血管性痴呆、特发性膜性肾病的网络药理学作用机制研究 . 药学实践与服务, 2025, 43(3): 143-150. doi: 10.12206/j.issn.2097-2024.202312027
[5]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(12): 512-519. doi: 10.12206/j.issn.2097-2024.202401050
[6]	杨嘉宁, 赵一颖, 肖伟. 七味脂肝方对非酒精性脂肪性肝炎动物模型的药效学评价 . 药学实践与服务, 2024, 42(9): 389-398. doi: 10.12206/j.issn.2097-2024.202404096
[7]	何亚伦, 祁智, 常杰. 消胀通便膏在晚期肝癌患者阿片类药物相关性便秘中的应用研究 . 药学实践与服务, 2024, 42(12): 520-523. doi: 10.12206/j.issn.2097-2024.202309009
[8]	戴菲菲, 傅翔, 陈琼年, 俞苏纯. 上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(12): 528-532. doi: 10.12206/j.issn.2097-2024.202305005
[9]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[10]	桂明珠, 李静, 李志玲. 儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
[11]	段禹, 刘爱军. 活血化瘀法治疗血管性痴呆的研究进展 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202408045
[12]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
[13]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[14]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
[15]	王耀振, 徐灿, 吕顺莉, 田泾, 张东炜. 钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
[16]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062

点击查看大图

计量

文章访问数: 4650
HTML全文浏览量: 485
PDF下载量: 142
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

选择性雌激素受体调节剂研究现状

doi: 10.3969/j.issn.1006-0111.2016.01.001

Research progress on the selective estrogen receptor modulators

计量

选择性雌激素受体调节剂研究现状

doi: 10.3969/j.issn.1006-0111.2016.01.001

1. 第二军医大学药学院有机化学教研室, 上海 200433

2. 第二军医大学药学院有机化学教研室, 上海 200433;烟台大学药学院, 山东烟台 264005

English Abstract

Research progress on the selective estrogen receptor modulators

1. Department of Organic Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

2. Department of Organic Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China;School of Pharmacy, Yantai University, Yantai 264005, China

全文HTML

目录

留言板

选择性雌激素受体调节剂研究现状

doi: 10.3969/j.issn.1006-0111.2016.01.001

Research progress on the selective estrogen receptor modulators

计量

出版历程

选择性雌激素受体调节剂研究现状

doi: 10.3969/j.issn.1006-0111.2016.01.001

1. 第二军医大学药学院有机化学教研室, 上海 200433 2. 第二军医大学药学院有机化学教研室, 上海 200433;烟台大学药学院, 山东 烟台 264005

English Abstract

Research progress on the selective estrogen receptor modulators

1. Department of Organic Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China 2. Department of Organic Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China;School of Pharmacy, Yantai University, Yantai 264005, China

全文HTML

目录

1. 第二军医大学药学院有机化学教研室, 上海 200433

2. 第二军医大学药学院有机化学教研室, 上海 200433;烟台大学药学院, 山东烟台 264005

1. Department of Organic Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

2. Department of Organic Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China;School of Pharmacy, Yantai University, Yantai 264005, China